류마티스질환 환자에서 생물학적 제제 사용 시 B형 간염 바이러스의 재활성화: 스크리닝 및 치료 = Reactivation of Hepatitis B Virus in Patients with Rheumatologic Disease Treated with Biologic Disease Modifying Anti-rheumatic Drugs: Screening and Treatment

다국어 초록 (Multilingual Abstract)

Reactivation of hepatitis B virus (HBV) is not infrequently reported in patients with rheumatologic diseases treated with biologic disease modify anti-rheumatic drugs (DMARDs) such as a tumor necrosis factor-α inhibitor or a B cell depleting molecule. HBV reactivation is reported not only in patients with chronic hepatitis B but also in cases with resolved HBV where HBsAg is negative and anti-HBc positive. Studies suggest that with treatment using biologic DMARDs, the risk of HBV reactivation increases when HBsAg is positive independent of HBV DNA replication status, and in those with anti-HBc positive and serum HBV DNA positive. Therefore, testing for HBsAg as well as anti-HBc is important before initiating treatment with a biologic DMARD. In addition, evaluation of serum HBV DNA may be required when either HBsAg or anti-HBc turns out to be positive. Although series of reports suggest that prophylactic antiviral therapy in patients with higher risk of HBV reactivation would diminish morbidity and mortality from hepatic cause, solid guidelines pertaining to when to initiate and terminate HBV antiviral therapy and which agent should be used should be provided in the future. (J Rheum Dis 2015;22:282-287)

참고문헌 (Reference)

1 Chang MH., "The significance of spontaneous hepatitis B e antigen seroconversion in childhood : with special emphasis on the clearance of hepatitis B e antigen before 3 years of age" 22 : 1387-1392, 1995

2 de Franchis R., "The natural history of asymptomatic hepatitis B surface antigen carriers" 118 : 191-194, 1993

3 Vierling JM., "The immunology of hepatitis B" 11 : 727-759, 2007

4 Liu HL., "The effects of nucleoside analogue prophylactic treatment on HBV activation in HBcAb+ patients undergoing immunosuppressive therapy" 20 : 645-649, 2013

5 Chen XQ., "The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy" 29 : 1237-1241, 2012

6 Kishida D., "Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis" 21 : 215-218, 2011

7 Cheng AL., "Steroid-free chemotherapy decreases risk of hepatitis B virus(HBV)reactivation in HBV-carriers with lymphoma" 37 : 1320-1328, 2003

8 Gupta S., "Spontaneous reactivation in chronic hepatitis B : patterns and natural history" 12 : 562-568, 1990

9 Martinot-Peignoux M., "Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers" 36 : 543-546, 2002

10 McMahon BJ., "Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus" 135 : 759-768, 2001

11 Kim PS., "Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B" 64 : 1265-1268, 2012

12 Dong HJ., "Risk of hepatitis B virus(HBV)reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy : a meta-analysis" 57 : 209-214, 2013

13 Nard FD., "Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment : Extending perspective from old to newer drugs" 7 : 344-361, 2015

14 Ghrénassia E., "Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis" 79 : 100-101, 2012

15 Germanidis G., "Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept" 56 : 1420-1421, 2012

16 Nakamura J, "Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs" 2014

17 Chung SJ., "Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy" 36 : 2416-2420, 2009

18 Pyrpasopoulou A., "Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis" 31 : 403-404, 2011

19 Chen YC., "Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection" 123 : 1084-1089, 2002

20 Rossi G., "Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy" 115 : 58-62, 2001

21 Sim JG., "Prevalence and its changes of hepatitis b viral markers from 1988 to 1993 in Korean children" 38 : 1535-1539, 1995

22 Lau GK., "Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation" 36 : 702-709, 2002

23 Yoo BC., "Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea" 38 : 98-103, 2003

24 Kim YJ., "Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases" 37 : 346-350, 2010

25 Zacharakis GH., "Natural history of chronic HBV infection : a cohort study with up to 12 years follow-up in North Greece(part of the Interreg I-II/EC-project)" 77 : 173-179, 2005

26 Hui CK., "Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase" 46 : 395-401, 2007

27 Hwang JP., "Management of patients with hepatitis B who require immunosuppressive therapy" 11 : 209-219, 2014

28 Hoofnagle JH., "Management of hepatitis B : summary of a clinical research workshop" 45 : 1056-1075, 2007

29 Mitroulis I., "Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection" 72 : 308-310, 2013

30 Yeo W., "Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy" 22 : 927-934, 2004

31 Ministry of Health & Welfare, "Korea health statistics 2011:Korea national health and nutrition examination survey (KNHANESV-2)"

32 Lan JL., "Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy" 70 : 1719-1725, 2011

33 Droz N., "Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases" 65 : 1504-1514, 2013

34 Croagh CM., "Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B" 30 : 1115-1122, 2010

35 Tran TT., "Immune tolerant hepatitis B : a clinical dilemma" 7 : 511-516, 2011

36 Pérez-Alvarez R., "Hepatitis B virus(HBV)reactivation in patients receiving tumor necrosis factor(TNF)-targeted therapy : analysis of 257 cases" 90 : 359-371, 2011

37 Okamoto H., "Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen" 68 : 8102-8110, 1994

38 Jang JW., "Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy" 20 : 7675-7685, 2014

39 Yeo W., "Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab" 27 : 605-611, 2009

40 Lee YH., "Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs" 16 : 527-531, 2013

41 Kim SJ., "Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab : analysis from the Asia Lymphoma Study Group" 49 : 3486-3496, 2013

42 Gigi E., "Hepatitis B reactivation in a patient with rheumatoid arthritis with antibodies to hepatitis B surface antigen treated with rituximab" 17 : 91-93, 2013

43 Hui CK., "Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy" 54 : 1597-1603, 2005

44 Saab S., "Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma : a decision analysis model" 46 : 1049-1056, 2007

45 Lau GK., "Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy" 125 : 1742-1749, 2003

46 Yeo W., "Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy" 43 : 209-220, 2006

47 Yeo W., "Comprehensive analysis of risk factors associating with Hepatitis B virus(HBV)reactivation in cancer patients undergoing cytotoxic chemotherapy" 90 : 1306-1311, 2004

48 Li HR., "Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy" 18 : 877-883, 2011

49 Lok AS., "Chronic hepatitis B : update 2009" 50 : 661-662, 2009

50 Lok AS., "Chronic hepatitis B" 45 : 507-539, 2007

51 Hsu C., "Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection : a prospective study" 59 : 2092-2100, 2014

52 Lee PI., "Changes of serum hepatitis B virus DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children" 12 : 657-660, 1990

53 Tsai SL., "Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion" 89 : 87-96, 1992

54 Lok AS., "Acute exacerbations in Chinese patients with chronic hepatitis B virus(HBV)infection. Incidence, predisposing factors and etiology" 10 : 29-34, 1990

55 Hsu C., "A revisit of prophylactic lamivudine for chemotherapyassociated hepatitis B reactivation in non-Hodgkin's lymphoma : a randomized trial" 47 : 844-853, 2008

56 Ahn YO., "A review study on descriptive epidemiology of HBs antigen positivity in Korea" 4 : 35-45, 1982

57 Lok AS., "A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children" 8 : 1130-1133, 1988